Vivesto AB (VIVE) - Total Liabilities
Based on the latest financial reports, Vivesto AB (VIVE) has total liabilities worth Skr11.29 Million SEK (≈ $1.22 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Vivesto AB liquidity resilience to evaluate the company's liquid asset resilience ratio.
Vivesto AB - Total Liabilities Trend (2004–2025)
This chart illustrates how Vivesto AB's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see VIVE current and non-current assets.
Vivesto AB Competitors by Total Liabilities
The table below lists competitors of Vivesto AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Healthcare Triangle Inc
NASDAQ:HCTI
|
USA | $24.63 Million |
|
Eurasia Fonciere Investissements Société Anonyme
PA:EFI
|
France | €19.91 Million |
|
Techstep ASA
OL:TECH
|
Norway | Nkr587.55 Million |
|
ESV Inc
KQ:223310
|
Korea | ₩44.53 Billion |
|
Rewardle Holdings Ltd
AU:RXH
|
Australia | AU$10.12 Million |
|
Emerge Commerce Ltd
V:ECOM
|
Canada | CA$18.71 Million |
|
Big Rock Brewery Inc.
TO:BR
|
Canada | CA$25.10 Million |
Liability Composition Analysis (2004–2025)
This chart breaks down Vivesto AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Vivesto AB (VIVE) net asset quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.06 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Vivesto AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Vivesto AB (2004–2025)
The table below shows the annual total liabilities of Vivesto AB from 2004 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr24.46 Million ≈ $2.63 Million |
+68.09% |
| 2024-12-31 | Skr14.55 Million ≈ $1.57 Million |
-36.38% |
| 2023-12-31 | Skr22.87 Million ≈ $2.46 Million |
-24.89% |
| 2022-12-31 | Skr30.45 Million ≈ $3.28 Million |
-31.71% |
| 2021-12-31 | Skr44.59 Million ≈ $4.80 Million |
-74.78% |
| 2020-12-31 | Skr176.80 Million ≈ $19.03 Million |
-4.92% |
| 2019-12-31 | Skr185.96 Million ≈ $20.01 Million |
-16.36% |
| 2018-12-31 | Skr222.33 Million ≈ $23.93 Million |
-0.32% |
| 2017-12-31 | Skr223.04 Million ≈ $24.00 Million |
+0.83% |
| 2016-12-31 | Skr221.21 Million ≈ $23.81 Million |
+16.72% |
| 2015-12-31 | Skr189.53 Million ≈ $20.40 Million |
+36.49% |
| 2014-12-31 | Skr138.86 Million ≈ $14.94 Million |
-25.54% |
| 2013-12-31 | Skr186.48 Million ≈ $20.07 Million |
+47.97% |
| 2012-12-31 | Skr126.03 Million ≈ $13.56 Million |
+65.10% |
| 2011-12-31 | Skr76.33 Million ≈ $8.21 Million |
+191.93% |
| 2010-12-31 | Skr26.15 Million ≈ $2.81 Million |
-30.91% |
| 2009-12-31 | Skr37.85 Million ≈ $4.07 Million |
+5.45% |
| 2008-12-31 | Skr35.89 Million ≈ $3.86 Million |
+57.01% |
| 2007-12-31 | Skr22.86 Million ≈ $2.46 Million |
+117.80% |
| 2006-12-31 | Skr10.50 Million ≈ $1.13 Million |
+118.84% |
| 2005-12-31 | Skr4.80 Million ≈ $516.16K |
+2.90% |
| 2004-12-31 | Skr4.66 Million ≈ $501.61K |
-- |
About Vivesto AB
Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma. The company also provides Apealea, an injectable formulation of paclitaxel for the treatment of various cancers. In addition, it develops Cantri… Read more